Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Fax: 862 904 8163

Website: www.tonixpharma.com

Address:

26 Main Street, Suite 101, Chatham, United States

asweidan Oct. 27 at 9:19 PM

$TNXP Historical, meaning in the last 6 months, every time we had two good days we had a red day. I think that the trend will be stopped tomorrow. I think that we will continue this upward trend for one more day. We will reach $21.30 tomorrow, and probably go a little beyond that. Then Wednesday will come around. Unless we have positive news we will have a red day.

0 · Reply

Fng4noob Oct. 27 at 8:47 PM

$TNXP looking good💎💎💎

0 · Reply

hustledad Oct. 27 at 7:52 PM

$TNXP The best part of owning this is that downside risk is capped. At most, it's 10-15% from here. Upside though is a different story. Unlimited.

0 · Reply

Stockeye2 Oct. 27 at 7:30 PM

$TNXP Send it! 🚀 🫡

0 · Reply

T2HeadedEagle Oct. 27 at 7:21 PM

$TNXP $18 was the low and i predicted the drop, it held nice there so back up we go. $40-$60 range coming up.

0 · Reply

StockJayC Oct. 27 at 7:20 PM

$TNXP sales team out in full force. Cogs are turning and it’s time to execute! August and September start dates!

2 · Reply

WARBUD Oct. 27 at 7:01 PM

$TNXP We are sitting on another key zone. If we can push past 20.36, we most likely test 21..

0 · Reply

RoacHK1LLaH420 Oct. 27 at 6:50 PM

$TNXP A whole YEAR & HALF. Still waiting for the BOOM. 🤔🤔🤔⌚⏲️⏳🙄

1 · Reply

i8j0momma666 Oct. 27 at 6:01 PM

$TNXP

0 · Reply

LiquidThetaOptions Oct. 27 at 5:33 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TNXP Current Share Price: $19.82 Contracts: $TNXP June 18, 2026 $22 Calls Scale in: $7.10- $8.68 Scale out: $11.05-$14.20 Can Easily Capture: 60% ROI Blended DTE: 234 Days | Join Elites here: https://liquidtheta.com

0 · Reply

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 22, 2025, 7:00 AM EDT - 5 days ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 21, 2025, 7:00 AM EDT - 6 days ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 17, 2025, 7:00 AM EDT - 10 days ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 14, 2025, 7:00 AM EDT - 13 days ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 9, 2025, 7:00 AM EDT - 18 days ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Sep 30, 2025, 8:30 AM EDT - 27 days ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Sep 29, 2025, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Sep 18, 2025, 8:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Sep 17, 2025, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Sep 8, 2025, 7:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

Aug 19, 2025, 12:28 PM EDT - 2 months ago

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

Aug 16, 2025, 8:45 AM EDT - 2 months ago

Tonix Secures Fibromyalgia Approval - What Investors Should Know

Aug 15, 2025, 3:50 PM EDT - 2 months ago

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

Aug 15, 2025, 3:44 PM EDT - 2 months ago

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Aug 11, 2025, 4:15 PM EDT - 2 months ago

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 21, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Jul 10, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Jul 9, 2025, 4:01 PM EDT - 3 months ago

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Jul 7, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Jul 2, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 16, 2025, 11:30 AM EDT - 4 months ago

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

Jun 16, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Jun 13, 2025, 7:30 AM EDT - 4 months ago

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Jun 13, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Jun 10, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention

Jun 5, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

May 22, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

May 21, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

May 14, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

May 12, 2025, 4:30 PM EDT - 6 months ago

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Apr 29, 2025, 9:05 AM EDT - 6 months ago

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Apr 24, 2025, 7:55 AM EDT - 6 months ago

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Apr 16, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

Apr 9, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Apr 7, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Apr 2, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

Mar 31, 2025, 7:00 AM EDT - 7 months ago

Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Mar 27, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Mar 26, 2025, 2:30 AM EDT - 7 months ago

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

Mar 25, 2025, 8:16 AM EDT - 7 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

ARQT

Mar 24, 2025, 8:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Mar 20, 2025, 7:00 AM EDT - 7 months ago

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Mar 19, 2025, 8:15 AM EDT - 7 months ago

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

ABSI HQY

Mar 18, 2025, 4:30 PM EDT - 7 months ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 13, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

Mar 12, 2025, 7:30 AM EDT - 8 months ago

Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target

asweidan Oct. 27 at 9:19 PM

0 · Reply

Fng4noob Oct. 27 at 8:47 PM

$TNXP looking good💎💎💎

0 · Reply

hustledad Oct. 27 at 7:52 PM

$TNXP The best part of owning this is that downside risk is capped. At most, it's 10-15% from here. Upside though is a different story. Unlimited.

0 · Reply

Stockeye2 Oct. 27 at 7:30 PM

$TNXP Send it! 🚀 🫡

0 · Reply

T2HeadedEagle Oct. 27 at 7:21 PM

$TNXP $18 was the low and i predicted the drop, it held nice there so back up we go. $40-$60 range coming up.

0 · Reply

StockJayC Oct. 27 at 7:20 PM

$TNXP sales team out in full force. Cogs are turning and it’s time to execute! August and September start dates!

2 · Reply

WARBUD Oct. 27 at 7:01 PM

$TNXP We are sitting on another key zone. If we can push past 20.36, we most likely test 21..

0 · Reply

RoacHK1LLaH420 Oct. 27 at 6:50 PM

$TNXP A whole YEAR & HALF. Still waiting for the BOOM. 🤔🤔🤔⌚⏲️⏳🙄

1 · Reply

i8j0momma666 Oct. 27 at 6:01 PM

$TNXP

0 · Reply

LiquidThetaOptions Oct. 27 at 5:33 PM

0 · Reply

Terminator1 Oct. 27 at 5:32 PM

$TNXP we’re going to blow past it like it was standing still

0 · Reply

Manu56 Oct. 27 at 5:19 PM

$TNXP 😎 https://youtu.be/YyjPOM5Y1PY?si=GYTsS5Z-AaR_13OE

0 · Reply

tr53 Oct. 27 at 5:12 PM

$TNXP Sad-sad—probably won't even last the 20

0 · Reply

cled Oct. 27 at 4:46 PM

$TNXP

0 · Reply

BioCapitalist99 Oct. 27 at 4:37 PM

$CCCC $IMRX $NUVB $SLS $TNXP

0 · Reply

WARBUD Oct. 27 at 4:16 PM

$TNXP WARMACHINE was all over the bounce on the 19.90 and is now calling a key bounce zone at 20.16 with next major resistance at 20.36..

0 · Reply

Oldslapnuts Oct. 27 at 3:58 PM

$TNXP NOTHING BUT GLORY.

0 · Reply

CIOBRAN Oct. 27 at 3:57 PM

$TNXP A p-value of $0.0001$ means there is a $0.01\%$ probability of observing the results you did if the null hypothesis (that there is no real effect) were true. This is considered highly statistically significant, indicating very strong evidence to reject the null hypothesis and conclude that the effect is real, not due to chance. It suggests a very small chance the observed data occurred randomly.

0 · Reply

BioCapitalist99 Oct. 27 at 3:54 PM

$TNXP the stocks goes up and you don't like it. Goes down and you don't like it. May you learn the virtue of patience....I loaded below 20 again. I'm done accumulating. Now, if you believe in Tonmya getting some decent sales, wait and see. The stock will move sideaways 17-24 usd till real positive news comes out. Today 8k was positive but that's not the type of news that will make it rip.

1 · Reply

CIOBRAN Oct. 27 at 3:51 PM

$TNXP THEY WANT OUR SHARES....PIECES OF SHIT

0 · Reply

CIOBRAN Oct. 27 at 3:50 PM

$TNXP CAN'T BREAK 20.55 LOW VOLUMES AND FUCKING SHORTER SPECULATORS.

0 · Reply

Dan55115 Oct. 27 at 3:38 PM

$TNXP the daily chart is showing two Mornimg Star Bearish reversal patterns. This is a STRONG multi candle signal that we will be Bullish now!

0 · Reply

Market Cap	170.85M
Revenue (ttm)	10.09M
Net Income (ttm)	-130.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,288.80%
Debt to Equity Ratio	0.00

Volume	888,414
Avg Vol	1,321,418
Day's Range	N/A - N/A
Shares Out	8.77M
Stochastic %K	52%
Beta	1.87
Analysts	Strong Sell
Price Target	$69.00